Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial.

Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017 Feb 14;: Authors: Paramsothy S, Kamm MA, Kaakoush NO, Walsh AJ, van den Bogaerde J, Samuel D, Leong RW, Connor S, Ng W, Paramsothy R, Xuan W, Lin E, Mitchell HM, Borody TJ Abstract BACKGROUND: The intestinal microbiota is implicated in the pathogenesis of ulcerative colitis. Faecal microbiota transplantation is a novel form of therapeutic microbial manipulation, but its efficacy in ulcerative colitis is uncertain. We aimed to establish the efficacy of intensive-dosing, multidonor, faecal…

Read More

Tofacitinib for induction and maintenance therapy of Crohn’s disease: results of two phase IIb randomised placebo-controlled trials.

Related Articles Tofacitinib for induction and maintenance therapy of Crohn’s disease: results of two phase IIb randomised placebo-controlled trials. Gut. 2017 Feb 16;: Authors: Panés J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, D’Haens G, Panaccione R, Higgins PD, Colombel JF, Feagan BG, Chan G, Moscariello M, Wang W, Niezychowski W, Marren A, Healey P, Maller E Abstract OBJECTIVE: Tofacitinib is an oral, small-molecule Janus kinase inhibitor that is being investigated for IBD. We evaluated the efficacy and safety of tofacitinib for induction and maintenance treatment in patients with…

Read More

Clinical impact of immunomonitoring in the treatment of inflammatory bowel disease.

Related Articles Clinical impact of immunomonitoring in the treatment of inflammatory bowel disease. World J Gastroenterol. 2017 Jan 21;23(3):414-425 Authors: Tighe D, McNamara D Abstract Despite improvement in outcomes, loss of response (LOR) to tumor necrosis factor-alpha (TNFα) therapies is a big concern in the management of inflammatory bowel disease. LOR is associated with flares of disease, increased hospitalisation rates, need for surgical interventions, and decline in quality of life. LOR may be multifactorial, but immunogenicity makes a significant contribution. Traditionally doses of anti-TNFα have been adjusted based on clinical…

Read More

α2-Heremans-schmid glycoprotein (fetuin A) downregulation and its utility in inflammatory bowel disease.

Related Articles α2-Heremans-schmid glycoprotein (fetuin A) downregulation and its utility in inflammatory bowel disease. World J Gastroenterol. 2017 Jan 21;23(3):437-446 Authors: Manolakis AC, Christodoulidis G, Kapsoritakis AN, Georgoulias P, Tiaka EK, Oikonomou K, Valotassiou VJ, Potamianos SP Abstract AIM: To investigate the impact of inflammatory bowel disease (IBD) on α2-Heremans-Schmid Glycoprotein (AHSG/fetuin A) and potential associations with disease and patient characteristics. METHODS: AHSG serum levels were determined in treatment-naïve newly-diagnosed patients, 96 with ulcerative colitis (UC), 84 with Crohn’s disease (CD), 62 with diarrhea-predominant or mixed irritable bowel syndrome (IBS,…

Read More

IL23R single nucleotide polymorphisms could be either beneficial or harmful in ulcerative colitis.

Related Articles IL23R single nucleotide polymorphisms could be either beneficial or harmful in ulcerative colitis. World J Gastroenterol. 2017 Jan 21;23(3):447-454 Authors: Fischer S, Kövesdi E, Magyari L, Csöngei V, Hadzsiev K, Melegh B, Hegyi P, Sarlós P Abstract AIM: To investigate the association of seven single nucleotide polymorphisms (SNPs) of the IL23R gene with the clinical picture of ulcerative colitis (UC). METHODS: Genomic DNA samples of 131 patients (66 males, 65 females, mean age 55.4 ± 15.8 years) with Caucasian origin, diagnosed with UC were investigated. The diagnosis of…

Read More

Incidental adenocarcinoma in patients undergoing surgery for stricturing Crohn’s disease.

Related Articles Incidental adenocarcinoma in patients undergoing surgery for stricturing Crohn’s disease. World J Gastroenterol. 2017 Jan 21;23(3):472-477 Authors: Kristo I, Riss S, Argeny S, Maschke S, Chitsabesan P, Stift A Abstract AIM: To evaluate frequency and clinical course of incidental adenocarcinoma in patients with stricturing Crohn’s disease (CD). METHODS: In this study, consecutive patients, who were operated on for stricturing CD between 1997-2012, were included at an academic tertiary referral center. Demographic data and clinical course were obtained by an institutional database and individual chart review. Besides baseline characteristics,…

Read More

Efficacy and safety of stellate ganglion block in chronic ulcerative colitis.

Related Articles Efficacy and safety of stellate ganglion block in chronic ulcerative colitis. World J Gastroenterol. 2017 Jan 21;23(3):533-539 Authors: Zhao HY, Yang GT, Sun NN, Kong Y, Liu YF Abstract AIM: To investigate the efficacy and safety of stellate ganglion block for the treatment of patients with chronic ulcerative colitis. METHODS: A total of 120 randomly selected patients with chronic ulcerative colitis treated in Cangzhou Central Hospital from January 2014 to January 2016 were included in this study. These patients were divided into two groups: control group (n =…

Read More

Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn’s disease.

Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn’s disease. Aliment Pharmacol Ther. 2017 Feb 17;: Authors: Yarur AJ, Kanagala V, Stein DJ, Czul F, Quintero MA, Agrawal D, Patel A, Best K, Fox C, Idstein K, Abreu MT Abstract BACKGROUND: Infliximab has been found to be efficacious in the treatment of fistulas in the setting of Crohn’s disease, even though some patients do not benefit from therapy. AIM: To assess the correlation between perianal fistula healing and trough levels of infliximab. METHODS: In this…

Read More
<< Go Back